FDA: PPIs and Clostridium Difficile

Published Online: Friday, July 20, 2012
Follow Pharmacy_Times:
In this podcast, Steve Jackson, a pharmacist in the FDA’s division of drug information, warns that use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea.
 
To listen to the podcast, click here.
Related Articles
As a result of confusing sensations of breathlessness with asthma symptoms, overweight and obese children tend to report poorer asthma control and overuse rescue medications.
As nearly one-third of patients with gastroesophageal reflux disease are partial responders to proton pump inhibitors (PPIs), health care professionals could benefit from reliable methods that predict who will respond to PPIs and who will not.
The My GI Health tool tracks symptoms of gastroesophageal reflux disease over time, helping clinicians save time and improve patient care.
Latest Issues
$auto_registration$